and Welcome to our new subscribers,
CWNM has made headlines recently with numerous announcements regarding its extensive patented technology.
Back on December 19th, CWNM announced that its Controlled Drug Delivery Technology (CDDT) has the potential to revolutionize the manner in which we take oral medication.
CWNM's CDDT is a novel controlled-release technology that harnesses the principles of diffusion through precise mathematical formulas.
CWNM believes the spectrum and reliability of pharmacokinetic profiles achievable with this technology is superior to currently marketed devices and formulations. CWNM's simple design allows for a high level of flexibility in matching chronotherapeutic requirements. Cost-efficiencies in the commercial manufacturing process, when compared to other drug delivery technologies, may constitute its most important competitive advantage.
On January 16th, CWNM announced that it's Controlled Drug Delivery Technology (CDDT) will focus on utilizing its unique and novel controlled drug delivery device to assist pharmaceutical companies in their lifecycle management strategies to extend patent life for blockbuster drugs.
Japanese Patent Application
On January 17th, CWNM announced it's Japanese Patent application, Sustained Release Delivery Systems for Solutes, has been approved and registered.
The intellectual property supporting the Controlled Drug Delivery Technology (CDDT) is comprehensively formulated to allow for the broad application of the technology with regard to the mode of administration, the desired release pattern, the type of compounds employed and the dosage form.
The technology can be employed to regulate time to first release of drug, the extent of the initial bolus release and the duration of the remaining controlled release. These programmable release profiles may be adjusted for considerations given to the different gastric and intestinal environments.
The technology is suited for the formulation of nutraceuticals, prescription and OTC drugs. In particular, the patent applications cover drug delivery devices that allow for linear, sustained-release of solutes with adjustable initial release kinetics.
**BLOCK BUSTER NEWS RELEASED THIS MORNING***
Just this morning CWNM made further progress by announcing that it's patent Counsel in India has filed a Statement regarding the working of the patented invention on a commercial scale in India in the matter of Patent No. 204009.
CWNM is committed to developing and licensing its CDDT technology in one of the fastest growing pharmaceutical markets in the world. By submitting this filing, Crown has preserved its patent rights in India.
Continue your research on CWNM at the companies website & make sure to have CWNM on your screen tomorrow morning because with such recent positive news being released the stock could see big gains ahead!
Follow Us On Twitter @AwesomeStocks (Nearly 1,000,000 follow!)